Renamed to Biora Therapeutics (NASDAQ:BIOR) in July 2022
PROG - Progenity, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
PROG price evolution
PROG
| (in millions $) | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $88.4 | $54.14 | $65.99 | $65.28 |
| Short term investments | ||||
| Net receivables | $0.65 | $1.92 | $5.05 | $13.21 |
| Inventory | $12.38 | |||
| Total current assets | $98.43 | $92.97 | $114.33 | $101.17 |
| Long term investments | ||||
| Property, plant & equipment | $4.01 | $4.56 | $5.47 | $17.38 |
| Goodwill & intangible assets | $6.07 | $9.83 | ||
| Total noncurrent assets | $10.41 | $4.71 | $5.62 | $27.41 |
| Total investments | ||||
| Total assets | $108.84 | $97.68 | $119.95 | $128.58 |
| Current liabilities | ||||
| Accounts payable | $8.71 | $7.99 | $14.56 | $15.63 |
| Deferred revenue | ||||
| Short long term debt | $0.01 | $0.11 | $0.2 | $0.5 |
| Total current liabilities | $61.61 | $103.27 | $85.64 | $80.06 |
| Long term debt | $126.39 | $157.26 | $158.77 | $161.94 |
| Total noncurrent liabilities | $132.21 | $171.37 | $173.92 | $174.02 |
| Total debt | $126.4 | $157.37 | $158.97 | $162.44 |
| Total liabilities | $193.81 | $274.65 | $259.56 | $254.08 |
| Shareholders' equity | ||||
| Retained earnings | -$788.69 | -$695.81 | -$652.07 | -$573.54 |
| Other shareholder equity | $0.22 | $0.22 | $0.23 | |
| Total shareholder equity | -$84.98 | -$176.97 | -$139.61 | -$125.51 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $88.4 | $92.08 | $33.04 | $49.01 |
| Short term investments | $20.2 | |||
| Net receivables | $0.65 | $12.68 | $22.19 | $8.15 |
| Inventory | $12.22 | $10.94 | $7.62 | |
| Total current assets | $98.43 | $126.34 | $74.65 | $88.95 |
| Long term investments | ||||
| Property, plant & equipment | $4.01 | $17.84 | $15.89 | $15.34 |
| Goodwill & intangible assets | $6.07 | $10.06 | $10.99 | |
| Total noncurrent assets | $10.41 | $28.1 | $27.08 | |
| Total investments | ||||
| Total assets | $108.84 | $154.44 | $101.73 | $116.4 |
| Current liabilities | ||||
| Accounts payable | $8.71 | $17.41 | $15.75 | $11.04 |
| Deferred revenue | ||||
| Short long term debt | $0.01 | $0.58 | $0.97 | $1.23 |
| Total current liabilities | $61.61 | $72.67 | $100.34 | $78.06 |
| Long term debt | $126.39 | $161.73 | $72.41 | $71.51 |
| Total noncurrent liabilities | $132.21 | $188.76 | $85.26 | |
| Total debt | $126.4 | $162.31 | $73.37 | |
| Total liabilities | $193.81 | $261.43 | $185.6 | $153.37 |
| Shareholders' equity | ||||
| Retained earnings | -$788.69 | -$541.27 | -$348.48 | -$142.47 |
| Other shareholder equity | $0.23 | $0.23 | ||
| Total shareholder equity | -$84.98 | -$106.99 | -$83.87 | -$36.97 |
| (in millions $) | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.43 | $0.18 | $0.46 | $24.53 |
| Cost of revenue | $22.23 | |||
| Gross Profit | $0.43 | $0.18 | $0.46 | $2.29 |
| Operating activities | ||||
| Research & development | $8.48 | $12.23 | $13.4 | $11.67 |
| Selling, general & administrative | $12.11 | $18.52 | $22.71 | $36.87 |
| Total operating expenses | $20.59 | $30.74 | $36.12 | $48.54 |
| Operating income | -$20.16 | -$30.56 | -$35.65 | -$46.25 |
| Income from continuing operations | ||||
| EBIT | -$90.81 | -$40.29 | -$75.03 | -$28.74 |
| Income tax expense | -$0.12 | |||
| Interest expense | $2.19 | $3.46 | $3.5 | $3.52 |
| Net income | ||||
| Net income | -$92.87 | -$43.74 | -$78.53 | -$32.26 |
| Income (for common shares) | -$92.87 | -$43.74 | -$78.53 | -$32.26 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.25 | $74.31 | $143.99 | $127.97 |
| Cost of revenue | $93.43 | $100.49 | $92.08 | |
| Gross Profit | $1.25 | -$19.12 | $43.49 | $35.9 |
| Operating activities | ||||
| Research & development | $45.78 | $47.74 | $63.4 | $48.71 |
| Selling, general & administrative | $73.3 | $128.32 | $120.21 | $101.42 |
| Total operating expenses | $119.08 | $176.07 | $183.61 | $242.21 |
| Operating income | -$117.84 | -$195.19 | -$140.12 | -$114.24 |
| Income from continuing operations | ||||
| EBIT | -$234.9 | -$220.08 | -$139.54 | |
| Income tax expense | -$0.12 | -$37.53 | -$0.71 | $5.25 |
| Interest expense | $12.64 | $9.98 | $9.2 | |
| Net income | ||||
| Net income | -$247.41 | -$192.53 | -$148.04 | -$129.11 |
| Income (for common shares) | -$247.41 | -$192.8 | -$228.83 | -$129.11 |
| (in millions $) | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 |
|---|---|---|---|---|
| Net income | -$92.87 | -$43.74 | -$78.53 | -$32.26 |
| Operating activities | ||||
| Depreciation | $0.37 | $0.1 | -$0.28 | $1.25 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.4 | $3.94 | $3 | $2.63 |
| Total cash flows from operations | -$40.05 | -$43.19 | -$35.69 | -$48.56 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0.39 | -$0.46 | |
| Investments | ||||
| Total cash flows from investing | $0.21 | -$0.43 | -$0.56 | -$0.46 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $69.37 | $40.05 | $38.37 | $24.43 |
| Net borrowings | $5.65 | -$8.15 | -$0.76 | -$2.13 |
| Total cash flows from financing | $73.54 | $31.77 | $37.52 | $22.23 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $33.7 | -$11.86 | $1.27 | -$26.8 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$247.41 | -$192.53 | -$148.04 | -$129.11 |
| Operating activities | ||||
| Depreciation | $1.44 | $5.06 | $6.35 | $6.07 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.96 | $10.67 | $2.38 | |
| Total cash flows from operations | -$167.49 | -$165.74 | -$106.12 | -$65.13 |
| Investing activities | ||||
| Capital expenditures | -$0.85 | -$4.94 | -$3.73 | -$4.83 |
| Investments | $20.25 | |||
| Total cash flows from investing | -$1.24 | -$4.94 | $16.52 | $55.83 |
| Financing activities | ||||
| Dividends paid | -$4.5 | |||
| Sale and purchase of stock | $172.22 | $116.44 | $0.55 | -$10.81 |
| Net borrowings | -$5.39 | $91.98 | -$1.27 | -$1.75 |
| Total cash flows from financing | $165.05 | $229.72 | $73.64 | -$12.81 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.68 | $59.03 | -$15.96 | -$22.1 |
News
|
Why Aterian Is the Top Short-Squeeze Stock Pick for May
TheStreet.com
4 May 2022
|
|
Intrinsic Medicine Stock: Leveraging Human Identical Milk Oligosaccharides (INRX)
Seeking Alpha
14 Apr 2022
|
|
53 Biggest Movers From Yesterday
Benzinga
30 Mar 2022
|
|
10 Best Biotech Stocks Under $5
Insider Monkey via Yahoo Finance
29 Mar 2022
|
|
20 Stocks Moving in Tuesday's Pre-Market Session
Benzinga
29 Mar 2022
|
|
Best Reddit Penny Stocks to Watch During Trading Today
St. Joseph News-Press
25 Mar 2022
|
|
Should You Invest in These Penny Stocks Next Month? 3 to Watch
St. Joseph News-Press
23 Mar 2022
|
|
3 Penny Stocks With Massive Upside Potential
TheStreet.com
22 Feb 2022
|
|
18 Stocks Moving in Wednesday's Pre-Market Session
Benzinga
26 Jan 2022
|
|
51 Biggest Movers From Yesterday
Benzinga
26 Jan 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 181.87M |
| Revenue | $25.61M |
|---|---|
| EBITDA | -$233.43M |
| EBIT | -$234.87M |
| Net Income | -$247.41M |
| Revenue Q/Q | -96.95% |
| Revenue Y/Y | -65.54% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | -0.47 |
| Cash/Share | 0.49 |
| EPS | -$1.36 |
|---|---|
| ROA | -217.48% |
| ROE | 187.77% |
| Debt/Equity | -2.28 |
|---|---|
| Net debt/EBITDA | -0.45 |
| Current ratio | 1.60 |
| Quick ratio | 1.60 |